Antonina Kolesnikova, MD
Nephrology · Washington, DCNPI 1598932592
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,421 of the $7,233 with a category attached, or 88.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,768 and has fallen 54.4% since, to $806 in 2025.
Across 262 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- AstraZeneca$686
- Fresenius USA Marketing, Inc.$660
- Novo Nordisk$656
- OPKO Pharmaceuticals, LLC$601
- Ardelyx, Inc.$583
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,42189%
- Education$81111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 36 | $1,025 |
| AstraZeneca | 23 | $686 |
| Fresenius USA Marketing, Inc. | 22 | $660 |
| Novo Nordisk | 19 | $656 |
| OPKO Pharmaceuticals, LLC | 32 | $601 |
| Ardelyx, Inc. | 16 | $583 |
| Mallinckrodt Enterprises LLC | 6 | $324 |
| Otsuka America Pharmaceutical, Inc. | 8 | $289 |
| Amgen(2 entities) | 10 | $269 |
| Vifor Pharma, Inc. | 10 | $245 |
| Akebia Therapeutics Inc | 10 | $228 |
| AbbVie | 13 | $211 |
| Lilly USA, LLC | 8 | $202 |
| Merck | 7 | $199 |
| Nxstage Medical, Inc. | 1 | $133 |
| Aurinia Pharma U.S., Inc. | 5 | $124 |
| Bayer | 6 | $124 |
| Inspire Medical Systems, Inc. | 2 | $110 |
| Amarin Pharma, Inc. | 4 | $82 |
| GSK | 3 | $75 |
| Boston Scientific | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Novartis | 2 | $37 |
| Travere Therapeutics, Inc. | 1 | $33 |
| Calliditas Therapeutics US Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Aerin Medical Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Bausch Health US, LLC | 1 | $24 |
| Medtronic | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$372
- Velphoro$251
- Ozempic$248
- PUREFLOW SL$133
- NXSTAGE SYSTEM ONE$133
- XPHOZAH 30 MG$122
- FARXIGA$121
- JYNARQUE$121
- LOKELMA$104
How this compares
$7,233 in reported general payments places this provider in the 80th percentile of 62 nephrology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 150 | $136,631 |
| VelphoroSucroferric Oxyhydroxide | 32 | $100,198 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $31,939 |
| JardianceEmpagliflozin | 41 | $27,221 |
| KerendiaFinerenone | 16 | $14,029 |
| JanuviaSitagliptin Phosphate | 17 | $12,659 |
| Sevelamer Carbonate | 28 | $9,832 |
| DapagliflozinDapagliflozin Propanediol | 13 | $7,280 |
| Midodrine Hcl | 23 | $1,763 |
| SpsSodium Polystyrene Sulfon/Sorb | 13 | $1,692 |
| Candesartan Cilexetil | 15 | $1,304 |
| Tamsulosin Hcl | 25 | $844 |
| Tacrolimus | 19 | $760 |
| Calcitriol | 29 | $700 |
| Amlodipine Besylate | 50 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $686 | $168,570178 claims |
| Fresenius USA Marketing, Inc.Velphoro | $660 | $100,19832 claims |
| BayerKerendia | $124 | $14,02916 claims |
| MerckJanuvia | $199 | $12,65917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 62 nephrology providers in District of Columbia.
Other nephrology in Washington
- Ashte CollinsWashington$1M
- Bruce LeslieWashington$217K
- Janani RangaswamiWashington$152K
- Robert RubinWashington$119K
- Ehsan Nobakht HaghighiWashington$50K
- Christopher WilcoxWashington$41K
- Michael LipkowitzWashington$21K
- Dominic RajWashington$19K
- Cosette JamiesonWashington$13K
- Elwin BustosWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.